Related Experiment Videos
Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
M B Møller1, Y Ino, A M Gerdes
1Department of Pathology, Odense University, Denmark.
Abstract:
The two gene products of the CDKN2A gene, p16 and p19ARF, have recently been linked to each of two major tumour suppressor pathways in human carcinogenesis, the RB1 pathway and the p53 pathway. p16 inhibits the phosphorylation of the retinoblastoma gene product by cyclin D-dependent kinases, whereas p19ARF targets MDM2, a p53 inhibitory protein, for degradation. A deletion of CDKN2A would therefore disturb both pathways. To explore the p53 pathway genes as a functional unit in diffuse large B cell non-Hodgkin's lymphomas (DLCL), we wanted to see whether there exists mutually exclusiveness of aberrations of CDKN2A, MDM2 and p53, since this has not been analysed previously. We investigated 37 DLCL for aberrations of p15, p16, p19ARF, MDM2, and p53 at the epigenetic, genetic and/or protein levels. Homozygous deletion of CDKN2A was detected in seven (19%) of 37 tumours, and another three cases were hypermethylated at the 5' CpG island of p16. No point mutations were found in CDKN2B or CDKN2A. Immunohistochemical staining of formalin-fixed, paraffin-embedded tissue for p16 confirmed these results, as all tumours with alterations of CDKN2A were p16 immunonegative. We found p53 mutations in eight (22%) cases and MDM2 overexpression in 16 (43%) tumours. Twenty-three (62%) tumours had alterations of one or more p53 pathway components (p53, p19ARF and MDM2). Furthermore, 7/9 (78%) p16-immunonegative tumours showed co-aberration of p53 and/or MDM2. The lack of correlation between these aberrations suggests that DLCL acquire additional growth advantage by inactivating both of these critical regulatory pathways.
Insights
Aberrations in the CDKN2A gene, impacting the RB1 and p53 tumor suppressor pathways, are common in diffuse large B-cell lymphoma (DLCL). These alterations, along with p53 and MDM2 changes, suggest DLCL gains growth advantage by disabling both critical regulatory pathways.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The CDKN2A gene encodes p16 and p19ARF, crucial tumor suppressors in the RB1 and p53 pathways.
- Aberrations in these pathways are implicated in human carcinogenesis.
- The interplay of CDKN2A, MDM2, and p53 in diffuse large B-cell lymphoma (DLCL) requires further investigation.
Purpose of the Study:
- To investigate the mutual exclusivity of aberrations in CDKN2A, MDM2, and p53 in DLCL.
- To analyze the p53 pathway genes as a functional unit in DLCL pathogenesis.
- To determine if DLCL acquires growth advantage by inactivating these critical regulatory pathways.
Main Methods:
- Analysis of 37 DLCL tumors for epigenetic, genetic, and protein-level aberrations.
- Investigated alterations in p15, p16, p19ARF, MDM2, and p53.
- Utilized homozygous deletion analysis, 5' CpG island methylation, point mutation analysis, and immunohistochemical staining for p16.
Main Results:
- Homozygous deletion of CDKN2A occurred in 19% of tumors; 8% showed p16 hypermethylation.
- p53 mutations were found in 22% and MDM2 overexpression in 43% of tumors.
- 62% of tumors had alterations in at least one p53 pathway component (p53, p19ARF, MDM2), with 78% of p16-negative tumors showing co-aberrations.
Conclusions:
- Alterations in CDKN2A, MDM2, and p53 are frequent in DLCL.
- The lack of correlation suggests co-inactivation of RB1 and p53 pathways provides a growth advantage.
- These findings highlight the importance of these pathways in DLCL development.